Manufacturing and Supply Partnering Terms and Agreements in Pharma, Biotech and Diagnostics

3423 pages report Published in
Pharmaceuticals
Publisher: Current Partnering

The Manufacturing and Supply Partnering Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the manufacturing and supply agreements entered into by the world’s biopharma companies. The report provides a detailed understand and analysis of how and why companies enter manufacturing and supply deals.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all manufacturing and supply deals announced since 2009 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual manufacturing and supply contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of manufacturing and supply dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in manufacturing and supply  deal making as well as a discussion on the merits of the type of deal.

Chapters 3 and 4 provide an overview of the structure of manufacturing and supply deals. The chapter includes numerous case studies to enable understanding of both pure manufacturing and supply deals and multicomponent deals where manufacturing and supply forms a part.

Chapters 5 and 6 provide a review of the leading manufacturing and supply deals since 2009. Deals are listed by headline value, signed by big pharma and big biotech, most active big pharma and big biotech, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 7 provides a comprehensive listing of the top 50 big pharma companies with a brief summary followed by a comprehensive listing of manufacturing and supply deals available in the public domain. Where available, each deal title links via Current Agreements deals and alliances database to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 8 provides a comprehensive listing of the top 50 big biotech companies with a brief summary followed by a comprehensive listing of manufacturing and supply deals available in the public domain. Where available, each deal title links via Current Agreements deals and alliances database to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapters 9 and 10 provide a comprehensive and detailed review of manufacturing and supply deals signed and announced since 2009 for all pharma, biotech, device and diagnostics companies where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the asset purchase deal.

In addition the report includes a comprehensive listing of all manufacturing and supply deals announced since 2009.

Each listing is organized as an appendix by company A-Z, stage of development at signing, and therapeutic area. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.

The report also includes numerous table and figures that illustrate the trends and activities in manufacturing and supply dealmaking since 2009.

In conclusion, this report provides everything a prospective dealmaker needs to know about manufacturing and supply alliances.

Benefits

Manufacturing and Supply Partnering Terms and Agreements in Pharma, Biotech and Diagnostics provides the reader with the following key benefits:

  • In-depth understanding of manufacturing and supply deal trends since 2009
  • Analysis of the structure of manufacturing and supply agreements with numerous real life case studies
  • Comprehensive access to over 2,500 actual manufacturing and supply deals entered into by the world’s biopharma companies
  • Detailed access to actual manufacturing and supply deals entered into by the leading fifty bigpharma and bigbiotech companies
  • Comprehensive access to all manufacturing and supply deals entered since 2009
  • Insight into the terms included in a manufacturing and supply agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

Manufacturing and Supply Partnering Terms and Agreements in Pharma, Biotech and Diagnostics is intended to provide the reader with an in-depth understanding of the manufacturing and supply trends and structure of deals entered into by pharma, biotech, device and diagnostics companies worldwide.

Manufacturing and Supply Partnering Terms and Agreements in Pharma, Biotech and Diagnostics includes:

  • Trends in manufacturing and supply dealmaking in the biopharma industry since 2009
  • Analysis of manufacturing and supply deal structure
  • Case studies of real-life manufacturing and supply deals
  • Access to over 2,500 manufacturing and supply deal records covering pharma, biotech, devices and diagnostics since 2009
  • The leading manufacturing and supply deals by value since 2009
  • Most active manufacturing and supply dealmakers since 2009
  • The leading manufacturing and supply partnering resources

In Manufacturing and Supply Partnering Terms and Agreements in Pharma, Biotech and Diagnostics, the available deals are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Therapeutic area
  • Technology type

Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.

Table of Contents

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in manufacturing and supply dealmaking
2.1. Introduction
2.2. Difference between manufacturing and supply deals
2.3. Trends in manufacturing deals since 2009
2.4. Trends in supply deals since 2009
2.4.1. When supply can be useful
2.5. Attributes of pure manufacturing and supply deals
2.6. Attributes of manufacturing and supply in multi-component deals
2.7. Reasons for including manufacturing and supply options in a multicomponent deal
2.8. The future of manufacture and supply as part of multicomponent deals

Chapter 3 – Overview of manufacturing and supply deal structure
3.1. Introduction
3.2. Pure versus multi-component manufacturing deals
3.3. Pure manufacturing agreement structure
3.3.1. Example manufacturing agreements
3.3.1.a. Case study 1: Amyris Brazil – Biomin Nutricao Animal Do Brasil
3.3.1.b. Case study 2: Patheon – Orexigen Therapeutics
3.4. Manufacturing rights as part of a wider alliance agreement
3.4.1. Example multicomponent manufacturing clauses
3.4.1.a. Case study 3: Agenus Bio – NewVac
3.4.1.b. Case study 4: Elite Pharmaceuticals – Hi-Tech Pharmacal

Chapter 4 – Overview of supply deal structure
4.1. Introduction
4.2. Supply agreement structure
4.2.1. Example supply agreements
4.2.1.a. Case study 5: Omthera Pharmaceuticals – Catalent Pharma solutions
4.2.1.b. Case study 6: Endo Pharmaceuticals – Noramco
4.3. Supply rights as part of a wider alliance agreement
4.3.1. Example co-marketing right clauses
4.3.1.a. Case study 7: Auxilium Pharmaceuticals – Asahi Kasei
4.3.1.b. Case study 8: Durata Therapeutics – Hospira

Chapter 5 – Leading manufacturing deals
5.1. Introduction
5.2. Top manufacturing deals by value
5.3. Most active manufacturing dealmakers
5.4. Big pharma manufacturing deal activity
5.5. Big biotech manufacturing deal activity

Chapter 6 – Leading supply deals
6.1. Introduction
6.2. Top supply deals by value
6.3. Most active supply dealmakers
6.4. Big pharma supply deal activity
6.5. Big biotech supply deal activity

Chapter 7 – Big pharma manufacturing and supply deals
7.1. Introduction
7.2. How to use manufacturing and supply deals
7.3. Big pharma company manufacturing and supply deal profiles
Abbott
Actavis
Allergan
Amgen
Astellas
Astellas Pharma Hong Kong
AstraZeneca
Baxter International
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
CSL
Daiichi Sankyo
Dainippon Sumitomo
Eisai
Eli Lilly
Endo Pharmaceuticals
Forest Laboratories
Fresenius
Galderma
Gilead Sciences
GlaxoSmithKline
Grifols
Hospira
Johnson & Johnson
Kyowa Hakko Kirin
Lundbeck
Menarini
Merck & Co
Merck KGaA
Mylan
Novartis
Novo Nordisk
Otsuka
Pfizer
Purdue
Ranbaxy Laboratories
Roche
Roche Diagnostics
Sanofi
Servier
Shionogi
Shire
Takeda
Teva
UCB
Valeant
Warner Chilcott

Chapter 8 – Big biotech manufacturing and supply deals
8.1. Introduction
8.2. How to use big biotech partnering deals
8.3. Big biotech manufacturing and supply partnering company profiles
3SBio
Acorda Therapeutics
Actelion
Alkermes
Anika Therapeutics
Bavarian Nordic
Biocon
Cangene
Cubist
Dendreon
Elan
Emergent BioSolutions
Enzo Biochem
Galapagos
Genmab
Ipsen
Isis Pharmaceuticals
LFB Group
Medivation
Morphosys
Nektar Therapeutics
NPS Pharmaceuticals
Onyx Pharmaceuticals
Optimer
Questcor Pharmaceuticals
SciClone Pharmaceuticals
Seattle Genetics
Spectrum Pharmaceuticals
Swedish Orphan Biovitrum
The Medicines Company
United Therapeutics
Vertex Pharmaceuticals
ViroPharma

Chapter 9 – Manufacturing deals contracts directory
9.1. Introduction
9.2. Company A-Z
9.3. By stage of development
9.4. By therapeutic target
9.5. By technology type

Chapter 10 – Supply deals contracts directory
10.1. Introduction
10.2. Company A-Z
10.3. By stage of development
10.4. By therapeutic target
10.5. By technology type

About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from CurrentPartnering
Order Form – Deal Type Reports
Order Form – Technology Type Reports

View the accompanying appendices for:
Appendix 1 – Company A-Z manufacturing deals
Appendix 2 – By therapy area - manufacturing
Appendix 3 – By stage of development at signing - manufacturing
Appendix 4 – By technology type – manufacturing
Appendix 5 – Company A-Z  - supply deals
Appendix 6 – By therapy area - supply
Appendix 7 – By stage of development at signing - supply
Appendix 8 – By technology type – supply
Appendix 9 –Dealmaking references
Appendix 10 – Resources
Appendix 11 – Deal type definitions
Appendix 12 – Example supply contract document

List of Figures

Figure 1: Definition of manufacturing and supply
Figure 2: Types of manufacturing agreement
Figure 3: Trends in manufacturing deal announcements, 2009-2014
Figure 4: Manufacturing deals signed by phase of development, 2009-2014
Figure 5: Trends in supply deal announcements, 2009-2014
Figure 6: Supply deals signed at what phase of development, 2009-2014
Figure 7: Components of the manufacturing deal structure
Figure 8: Components of the supply deal structure
Figure 9: Top manufacturing deals by value since 2009
Figure 10: Most active manufacturing dealmakers 2009-2014
Figure 11: Big pharma – top 50 – manufacturing deals 2009 to March 2014
Figure 12: Big pharma manufacturing deal frequency - 2009 to March 2014
Figure 13: Big biotech – top 50 – manufacturing deals 2009 to March 2014
Figure 14: Top supply deals by value since 2009
Figure 15: Most active supply dealmakers 2009-2014
Figure 16: Big pharma – top 50 – supply deals 2009 to 2014
Figure 17: Big pharma supply deal frequency - 2009 to 2014
Figure 18: Big biotech – top 50 – supply deals 2009 to 2014
Figure 19: Big biotech supply deal frequency - 2009 to 2014

Related Reports

  • Asset Purchase Terms and Agreements in Pharma, Biotech and Diagnostics
    The Asset Purchase Partnering Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the asset purchase agreements entered into by the worlds leading biopharma companies. The report provides a detailed understand and analysis of how and why companies enter asset purchase deals. Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms o...
  • Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics
    The Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the merger and acquisition agreements entered into by the worlds leading biopharma companies. The report provides a detailed understand and analysis of how and why companies enter merger and acquisition deals. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process...
  • Pharma and Biotech M&A Trends 2009-2014
    The Pharma and Biotech M&A Trends 2009-2014 report provides comprehensive understanding and unprecedented access to the merger and acquisition agreements entered into by the worlds leading biopharma companies. The report provides a detailed understand and analysis of how and why companies enter merger and acquisition deals. Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect ...
  • Licensing Terms and Agreements in Pharma, Biotech and Diagnostics
    The Licensing Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the licensing deals and agreements entered into by the worlds leading life science companies. The report provides a detailed understand and analysis of how and why companies enter licensing deals. Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you...
  • Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics
    The Collaborative R&D Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the collaborative R&D deals and agreements entered into by the worlds leading life science companies. The report provides a detailed understand and analysis of how and why companies enter collaborative R&D deals. Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the nego...